247 related articles for article (PubMed ID: 22212142)
1. Primary cutaneous B-cell lymphomas.
Kempf W; Denisjuk N; Kerl K; Cozzio A; Sander C
J Dtsch Dermatol Ges; 2012 Jan; 10(1):12-22; quiz 23. PubMed ID: 22212142
[TBL] [Abstract][Full Text] [Related]
2. Indolent cutaneous B-cell lymphoma: diagnosis and treatment 2012.
Santucci M; Grandi V; Maio V; Delfino C; Alterini R; Pimpinelli N
G Ital Dermatol Venereol; 2012 Dec; 147(6):581-8. PubMed ID: 23149704
[TBL] [Abstract][Full Text] [Related]
3. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
4. [Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group].
Grange F; D'Incan M; Ortonne N; Dalac S; Laroche L; Beylot-Barry M; Delfau-Larue MH; Vergier B; Bagot M;
Ann Dermatol Venereol; 2010; 137(8-9):523-31. PubMed ID: 20804896
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.
Kempf W; Kazakov DV; Mitteldorf C
Am J Dermatopathol; 2014 Mar; 36(3):197-208; quiz 209-10. PubMed ID: 24658377
[TBL] [Abstract][Full Text] [Related]
6. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
7. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
8. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M; Lucioni M; Maffi A; Croci GA; Nicola M; Berti E
G Ital Dermatol Venereol; 2012 Dec; 147(6):589-602. PubMed ID: 23149705
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
Nicolay JP; Wobser M
J Dtsch Dermatol Ges; 2016 Dec; 14(12):1207-1224. PubMed ID: 27992127
[TBL] [Abstract][Full Text] [Related]
11. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification.
Suárez AL; Pulitzer M; Horwitz S; Moskowitz A; Querfeld C; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):329.e1-13; quiz 341-2. PubMed ID: 23957984
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous B-cell lymphoma].
Cortés B; Prins C
Rev Med Suisse; 2014 Apr; 10(424):738, 740-3. PubMed ID: 24772806
[TBL] [Abstract][Full Text] [Related]
16. [Epitheliotropic lymphomas: better identification for improved treatment].
Bagot M
Bull Acad Natl Med; 2010 Oct; 194(7):1365-72. PubMed ID: 22043631
[TBL] [Abstract][Full Text] [Related]
17. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.
Suárez AL; Querfeld C; Horwitz S; Pulitzer M; Moskowitz A; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):343.e1-11; quiz 355-6. PubMed ID: 23957985
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
[TBL] [Abstract][Full Text] [Related]
20. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
Park MY; Jung HJ; Park JE; Kim YC
Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
